Granules is a large-scale backward integrated formulation manufacturer, partnering with market leaders to offer pharmaceutical products and services. We produce Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs). We support customers with unique value, extensive product range and a global network of associates.

We are a fully vertically integrated pharmaceutical manufacturing company with three core lines:

Finished Dosages (FD) ? Granules has a dedicated FD plant at our Gagillapur facility. Our plant has the capacity to produce 6 billion tablets annually and is scalable up to 12 billion tablets. The facility has received approval from Infarmed and the Australian TGA.

Pharmaceutical Formulation Intermediates (PFI) ? Granules pioneered the concept of PFIs and currently has 2 factories manufacturing single- and multiple- active PFIs. Our Gagillapur facility has an industry-leading 6 MT single batch size.

Active Pharmaceutical Ingredients (API) ? Granules has 3 factories manufacturing APIs. We are among the top global manufacturers of Paracetamol and Ibuprofen.

Our backward integrated formulation model allows us to provide products throughout the value chain in a cost-effective and efficient manner. We serve over 300 customers in 50 countries through our sales offices in India, U.S., U.K. and Colombia.

Our Value Proposition

Granules has a highly sophisticated production processes in order to manufacture a broad assortment of products, thereby supplying a wide range of products and services to our customers in a flexible and reliable manner. Our products can be used in a range of pharmaceutical applications, and we are constantly developing new products and variants to meet our customers' specific requirements.

We have demonstrated our commitment to the pharmaceutical industry through a high level of customer service. Our product specialists, supported by application technologists, research scientists and regulatory advisers are able to provide immediate advice and customer support. By offering unique products and a high level of customer support, we can offer our customers the competitive advantage that is vital in the highly competitive pharmaceutical sector.

Granules encourage its customers to replace their conventional strategy of captive manufacture with prudent outsourcing. Our value proposition comprises of the following:

• The manufacture of PFIs (strategically backward integrated through the in-house manufacture of APIs) to finished dosages (tablets in bulk).


• Putting customers at ease by filing ANDA / dossiers for finished dosages, which are repacked and marketed by the customers under their own brand name.


• Relief for customers from regulatory rigors as well as manufacturing and cleaning process validation responsibilities.


• Significant savings in sampling, analytical, regulatory, R&D and manufacturing resources.